Women respond better to biological therapy in Crohn's Disease

Detalhes bibliográficos
Autor(a) principal: Santos,Carlos Henrique Marques dos
Data de Publicação: 2014
Tipo de documento: Artigo
Idioma: eng
Título da fonte: MedicalExpress (São Paulo. Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2358-04292014000300150
Resumo: OBJECTIVE: Crohn's disease is in itself a major challenge for those treating inflammatory bowel diseases. Those exhibiting the fistulizing form, particularly perianal fistulas, create even more of a challenge, as there is great difficulty in obtaining disease control even using long-term therapeutic advances made in recent years. We evaluated the difference between the gender of patients under biological treatment for Crohn's Disease and perianal fistula. METHODS: We studied 30 patients with Crohn's Disease with perianal fistula with a mean age of 35 years, from 2000 to 2013. All were naïve to biological agents and received these medications in usual doses and intervals. All were also treated surgically with curettage and placement of seton-stitches prior to the use of biological agents. The results were analyzed statistically by Student's t test, p < 0.05 being considered a significant difference. RESULTS: Among responders, ten were men and nine were women, with no significant difference between genders in this regard. Among non-responders, eight were men and three were women: thus, significantly more men vs. women were non-responders. In general, 55% of men and 75% of women were responders. CONCLUSION: Women exhibited a lower failure rate when exposed to biological treatment for perianal fistula in Crohn's Disease when compared to men.
id METC-1_23d9aab1b9d8853a0014cb57d4acd217
oai_identifier_str oai:scielo:S2358-04292014000300150
network_acronym_str METC-1
network_name_str MedicalExpress (São Paulo. Online)
repository_id_str
spelling Women respond better to biological therapy in Crohn's DiseaseCrohn's diseaseInfliximabAdalimumabperianal fistulagender OBJECTIVE: Crohn's disease is in itself a major challenge for those treating inflammatory bowel diseases. Those exhibiting the fistulizing form, particularly perianal fistulas, create even more of a challenge, as there is great difficulty in obtaining disease control even using long-term therapeutic advances made in recent years. We evaluated the difference between the gender of patients under biological treatment for Crohn's Disease and perianal fistula. METHODS: We studied 30 patients with Crohn's Disease with perianal fistula with a mean age of 35 years, from 2000 to 2013. All were naïve to biological agents and received these medications in usual doses and intervals. All were also treated surgically with curettage and placement of seton-stitches prior to the use of biological agents. The results were analyzed statistically by Student's t test, p < 0.05 being considered a significant difference. RESULTS: Among responders, ten were men and nine were women, with no significant difference between genders in this regard. Among non-responders, eight were men and three were women: thus, significantly more men vs. women were non-responders. In general, 55% of men and 75% of women were responders. CONCLUSION: Women exhibited a lower failure rate when exposed to biological treatment for perianal fistula in Crohn's Disease when compared to men.Mavera Edições Técnicas e Científicas Ltda2014-06-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S2358-04292014000300150MedicalExpress v.1 n.3 2014reponame:MedicalExpress (São Paulo. Online)instname:Mavera Edições Científicas e Técnicas Ltda-MEinstacron:METC10.5935/MedicalExpress.2014.03.10info:eu-repo/semantics/openAccessSantos,Carlos Henrique Marques doseng2016-06-06T00:00:00Zoai:scielo:S2358-04292014000300150Revistahttp://www.medicalexpress.net.brhttps://old.scielo.br/oai/scielo-oai.php||medicalexpress@me.net.br2358-04292318-8111opendoar:2016-06-06T00:00MedicalExpress (São Paulo. Online) - Mavera Edições Científicas e Técnicas Ltda-MEfalse
dc.title.none.fl_str_mv Women respond better to biological therapy in Crohn's Disease
title Women respond better to biological therapy in Crohn's Disease
spellingShingle Women respond better to biological therapy in Crohn's Disease
Santos,Carlos Henrique Marques dos
Crohn's disease
Infliximab
Adalimumab
perianal fistula
gender
title_short Women respond better to biological therapy in Crohn's Disease
title_full Women respond better to biological therapy in Crohn's Disease
title_fullStr Women respond better to biological therapy in Crohn's Disease
title_full_unstemmed Women respond better to biological therapy in Crohn's Disease
title_sort Women respond better to biological therapy in Crohn's Disease
author Santos,Carlos Henrique Marques dos
author_facet Santos,Carlos Henrique Marques dos
author_role author
dc.contributor.author.fl_str_mv Santos,Carlos Henrique Marques dos
dc.subject.por.fl_str_mv Crohn's disease
Infliximab
Adalimumab
perianal fistula
gender
topic Crohn's disease
Infliximab
Adalimumab
perianal fistula
gender
description OBJECTIVE: Crohn's disease is in itself a major challenge for those treating inflammatory bowel diseases. Those exhibiting the fistulizing form, particularly perianal fistulas, create even more of a challenge, as there is great difficulty in obtaining disease control even using long-term therapeutic advances made in recent years. We evaluated the difference between the gender of patients under biological treatment for Crohn's Disease and perianal fistula. METHODS: We studied 30 patients with Crohn's Disease with perianal fistula with a mean age of 35 years, from 2000 to 2013. All were naïve to biological agents and received these medications in usual doses and intervals. All were also treated surgically with curettage and placement of seton-stitches prior to the use of biological agents. The results were analyzed statistically by Student's t test, p < 0.05 being considered a significant difference. RESULTS: Among responders, ten were men and nine were women, with no significant difference between genders in this regard. Among non-responders, eight were men and three were women: thus, significantly more men vs. women were non-responders. In general, 55% of men and 75% of women were responders. CONCLUSION: Women exhibited a lower failure rate when exposed to biological treatment for perianal fistula in Crohn's Disease when compared to men.
publishDate 2014
dc.date.none.fl_str_mv 2014-06-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2358-04292014000300150
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2358-04292014000300150
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.5935/MedicalExpress.2014.03.10
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Mavera Edições Técnicas e Científicas Ltda
publisher.none.fl_str_mv Mavera Edições Técnicas e Científicas Ltda
dc.source.none.fl_str_mv MedicalExpress v.1 n.3 2014
reponame:MedicalExpress (São Paulo. Online)
instname:Mavera Edições Científicas e Técnicas Ltda-ME
instacron:METC
instname_str Mavera Edições Científicas e Técnicas Ltda-ME
instacron_str METC
institution METC
reponame_str MedicalExpress (São Paulo. Online)
collection MedicalExpress (São Paulo. Online)
repository.name.fl_str_mv MedicalExpress (São Paulo. Online) - Mavera Edições Científicas e Técnicas Ltda-ME
repository.mail.fl_str_mv ||medicalexpress@me.net.br
_version_ 1754734596574937088